Drug Trial Radar · NCT05979051
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
166
Planned (sponsor's estimate)
Start
Nov 16, 2023
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
Conditions
- Eosinophilic Granulomatosis With Polyangiitis
Interventions
SHR-1703Drug
SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
Mepolizumab InjectionDrug
Mepolizumab Injection and Matching Placebo will be administered by Subcutaneous injection in Phase 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in oral glucocorticoid dose (OCS)Time frame: Up to week 12
- The Proportion of subjects in EGPA remissionTime frame: week 36 and week 48
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.